Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing unit in Telangana. This followed an earlier inspection that resulted in an 'Official Action Indicated' status. Aurobindo affirmed that current US supplies are unaffected and emphasized their commitment to enhancing compliance with regulatory standards.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.